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Q-MSH was found to decrease the recently characterized 
dopachrome tautomerase activity in cultures of B16/Fl0 
mouse melanoma cells. Other stimulating agents of melano-
genesis, like dibutyryl cyclic AMP, 3-isobutyl-l-methylx-
anthine, theophylline, retinol, and retinoic acid, caused the 
same effect. The grade of inhibition depended on the nature 
of the agent and the time of exposure. In all cases, both 
melanin production and tyrosinase activity were activated by 
T yrosinase (EC 1.14.18.1), the key enzyme in melano-genesis, has been thought for many years to be the only enzyme acting on the regulation of melanin bio-synthesis. However, in the last few years it has been shown that other regulatory factors play their role in 
the control of the distal steps of the pathway. Thus, the following 
factors have been reported: a) Dopachrome conversion factor, 
which accelerates the conversion of dopachrome into dihydroxyin-
doles [1J; b) 5,6-dihydroxyindole (DHI) conversion factor, which 
accelerates the conversion of D HI into melanin [1 J (this factor was 
thought to be active only in cells treated with melanocyte-stimulat-
ing hormone (MSH), but later it has been also reported that this 
factor could be actually the third activity of tyrosinase [2]); c) DHI 
blocking factor that inhibits melanin formation from DHI [1 J; and 
d) An enzyme termed dopachrome oxidoreductase that was thought 
to catalyze the conversion of dopachrome and also to act as an 
indole-blocking factor [3J. 
In the same way, the partial purification and characterization of 
OCT (EC 5.3.2.3), an enzyme with dopachrome converting activ-
ity, catalyzing the transformation of dopachrome into 5,6-dihy-
droxyindole-2-carboxylic acid (DHICA) was recently reported [4J. 
Probably, this enzyme would account for the dopachrome conver-
sion factor and the dopachrome oxidoreductase [5J. Furthermore, 
the high stability of DHICA can explain the apparent blocking 
effect in melanogenesis without the existence of a DHI blocking 
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these treatments, although the grade of tyrosine hydroxylase 
and dopa oxidase stimulation was different. Moreover, no 
correlation among the intensities of dopachrome tautomer-
ase inhibition and tyrosinase activation by the tested agents 
could be obtained. The significance of these results in the 
regulation of mammalian melanogenesis is discussed.] Invest 
Dermatol 99:435 -439, 1992 
factor. Therefore, it is plausible that melanogenesis is mainly regu-
lated by both enzymes, tyrosinase and DCT. 
In melanocytes, it is well known that melanotropins cause an 
increase in the activity of tyrosinase and the accumulation of mela-
nin [6,7J . Two hypotheses have been designed in order to under-
stand the mechanisms responsible for this stimulation of melano-
synthesis. On one hand, an increase in the rate of "de novo" 
synthesis of tyrosinase could be one of the possible explanations for 
this fact [8-10J. On the other hand, activation of pre-existing en-
zyme molecules could also contribute to the increase in tyrosinase 
activity [6,11]. These two mechanisms are not mutually exclusive. 
In any case, it has been proposed that these effects are mediated by an 
increase of the intracellular levels of cAMP [12J. This hypothesis is 
supported by the fact that agents increasing cAMP, such as theo-
phylline, IBMX or db-cAMP, also produce activation of tyrosinase 
l10,13]. However, the stimulation of tyrosinase activity is not 
always mediated by cAMP, and it has been reported that PGE1 and 
PGE2 increase this activity by a different way [14]. Furthermore, 
retinoids also stimulate tyrosinase activity, although the mecha-
nisms that would account for this stimulation still remain unclear 
[15]. 
Less information is available about the effect of melanotropins on 
the other factors/enzymes responsible for the regulation of the dis-
tal steps of melanogenesis. Thus, in Cloudman S91 cells, it was first 
described that dopachrome conversion factor did not seem to suffer 
any modification after treatment with MSH [1], but afterwards it 
was reported that this activity was stimulated by ,B-MSH treatment 
[16]. In turn, it has been published that dopachrome oxidoreductase 
from mice hairbulbs was stimulated after treatment with MSH [17] . 
It has also been reported that retinoic acid is a potent inhibitor of the 
stimulation of dopachrome conversion factor by ,B-MSH in Cloud-
man S91 cells [18]. Finally, very recent data obtained in JB/MS 
melanoma cells indicate that there is almost no change in the DCT 
activity of cells cultured in the presence or absence of a-MSH for 
4d[19]. 
We herein report the effects of a-MSH and other melanogenic 
agents on dopachrome tautomerase (DCT), tyrosine hydroxylase, 
and dopa oxidase activities in cultured B16/FI0 malignant mela-
noma cells. We have found that melanogenic agents provoke a 
significant decrease of DCT activity in B16 melanoma cells, 
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whereas tyrosinase activity increases. The different behavior of the 
two enzymes and their functions in the regulation of melanogenesis 
are discussed. 
MATERIALS AND METHODS 
Chemicals Theophylline, db-cAMP, IBMX, retinol, and reti-
noic acid were obtained from Sigma Chemical Co. (St. Louis, MO). 
a-MSH was from Boehringer Mannheim (Germany). The a-MSH 
analogue 4-NorLeu, 7-DPhe-a-MSH was kindly given by Dr. 
Ghanem from Institut Jules Bordet, Brussels, Belgium. All chemi-
cals were used at the highest commercially available purity. 
Culture media, fetal calf serum, Hanks' isotonic salt solution, and 
other reagents for malignant melanocyte culture were from Flow 
Lab (Irvine, Scotland). L-(3,5-3H)-tyrosine (specific activity 58.8 
Ci/mmol) was obtained from New England Nuclear (Boston, MA). 
All solutions were prepared with bi-distilled, deionized water, with 
a resistance higher than 10 Mil . cm. 
Cell Culture B16/FI0 melanocytes were maintained in mini-
mum essential medium (MEM) (Eagle, modified with Earle's salts 
and glutamine and without bicarbonate, containing 10% fetal calf 
serum). One hundred units per milliliter penicillin and 100,ug/ml 
streptomycin were also added to the medium. Cells were grown in 
75-cm2 flasks (Nunc, Roskilde, Denmark), at 37°C, in a water-sa-
turated 5% CO2 atmosphere. They were harvested by incubation in 
a solution of 0.1 mg/ml trypsin with 0.2 mg/ml EDTA in pH 7.2 
Hanks' without Ca(II) and Mg(I1), for 5 min and then shaking of 
the flask. Cells were pelleted by centrifugation at 1000 rpm for 10 
min at 22°C in a Heraeus Minifuge T. The pellet was resuspended 
in pH 7.2 Hanks' solution and cells were counted. A duplicate set of 
flasks was always used for every experiment. Cells were used be-
tween the third and the 30th passage. After this last passage, these 
cells were discarded and new cultures were initiated. 
Enzyme Assays Prior to assay enzyme activities, cells were 
disrupted by resuspending them in an hypotonic medium (10 roM 
phosphate buffer, pH 6.8, with 1 % Brij 35) followed by sonication 
in an ice-cold water bath for 5 min. After '· centrifugation at 
13,000 X g for 10 min in an Eppendorf centrifuge, the supernatant 
was used to measure enzymatic activities and protein content, wher-
eas melanin was quantified in the pellet. 
Tyrosinase Activity: Tyrosinase activity was determined by two dif-
ferent methods. a) By dopa oxidase, activity was measured spectro-
photometrically, by recording the absorbance increase at 475 nm, 
due to dopachrome formation (e = 3700 M-I cm- I), as described by 
Mason [20]. One unit of this activity was defined as the amount of 
enzyme that catalyzes the oxidation of l,umol of L-dopa per min at 
30°C. b) By tyrosine hydroxylase, assays were carried out according 
to Jara et al [21], using L-(3,5-3H)-tyrosine as substrate. One unit of 
tyrosine hydroxylase activity was defined as the amount of enzyme 
that catalyzes the hydroxylation of 1 pmol ofL-tyrosine per min at 
37°C. 
DeT Activity: . DCT activity was measured by two different meth-
ods, a) following the absorbance decrease at 475 nm due to do-
pachrome consumption [3]; and b) following the absorbance in-
crease at 308 nm, originated by the enzymatic formation ofDHICA 
from dopachrome [22]. In both cases, dopachrome was prepared by 
the stoichiometric oxidation of L-dopa by sodium periodate. One 
unit ofDCTwas defined as the amount of enzyme that catalyzes the 
transformation of l,umol of dopachrome per min at 30°C. 
Melanin and Protein Determination The melanin content 
was quantified by measuring the absorbance at 400 nm of melanin 
digested with hot 0.85 M KOH, using synthetic melanin as stan-
dard [15]. Protein estimation was performed as reported by Lowry et 
al [23] using BSA as standard. 
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Figure L Percentages of DCT activity after treatment of B16/FI0 mela-
noma cells with a-MSH (2 X 10-7 M), db-cAMP (0.5 mM), IBMX 
(0.5 mM), retinoic acid (0.01 mM), retinol (0.01 mM), and theophylltne 
(1 mM). 100% was considered the activity for control cells without any 
treatment (8.10 ± 0.20) munits/mg protein). Bars, SEM of duplicate exper-
iments. 
RESULTS 
B16/FI0 melanoma cells, seeded 24 h before: were treated with 
a -MSH in I-I,anks' isotonic solu.tio~ t~ give a final concent~ation oJ 
2 X 10-7 M 111 the culture media, Similar to the concentratIOn use 
in similar studies [6,19]. Simultaneously, other cells seeded at th~ 
same conditions were treated with an identical volume of Hanks 
salt solution exented of a-MSH. Both sets of cells were maintained 
in the respective media for periods between 1 and 4 d. Afterward~, 
cells at approximately 80% confluence were collected and their 
DCT and tyrosinase activities, as well as melanin and protein con-
tents, were measured. 
After 1 d, a significant decrease in DCT activity could be ob-
served; specific activities were 8.10 ± 0.20 munits/mg for the. con- . 
trol cells and 2.92 ± 0.66 munits/mg for the treated ones (FI~ 1), 
which is a 64% of inhibition as compared to the control actlvlry· . 
Tyrosinase activities were also tested on these cells. Treatment 
with a-MSH resulted in an increase of tyrosinase activities, as re-
ported by others. However, the degree of activation was different 
for dopa oxidation and tyrosine hydroxylation. Dopa oxidase actiVS ity for the control was 4.41 ± 0.53 munits/mg and 6.32 ± O.~ 
munits/mg for the treated cells, showing a stimulation of on Y 
143% (Fig 2), whereas tyrosine hydroxylase for the control and .fo
/
r 
the treated cells were 1.92 ± 0.45 units/mg and 6.9 ± 1.23 units 
mg, respectively, being a 360% stimulation of this activity. ante 
other hand, after the treatment with a-MSH for 24 h, the vlabl 11. 
of cells was about 85% with respect to the untreated control. . 
similar pattern of differential activation of both tyrosinase activities 
was obtained for theophylline-treated cells (not shown). In the same 
way, melanin synthesis was increased after a-MSH treatment. 
Thus, the melanin content for the control was 3.08 ± 0.22 ,ug/mg 
protein and 5.98 ± 0.54 ,ug/mg protein for the melanoma cultures 
treated with hormone (Fig 2). 
Figure 3 shows the time course of the variation of DCT,. dopa 
oxidase, and tyrosine hydroxylase activities, as well as melanm a~­
cumulation, after treatment with a-MSH for 24 h. The decreaset 
the DCT activity can be observed as early as 2 h after addition of~ 1: 
hormone. If a second dose of a-MSH is added 24 h after the r~ 
treatment, there is no further decrease in DCT activity after a ne s 
24 h period. As could be expected, there is a slow and continUou 
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Figure 2. Percentages of dopa oxidase activity and melanin content after 
treatment of B16/F10 melanoma cells with a-MSH (2 X 10- 7 M), db-
cAMP (0.5 mM), IBMX (0.5 mM), retinoic acid (0.01 mM), retinol 
(0.01 mM), and theophylline (1 mM). 100% was considered the activity and 
the melanin content for control cells without any treatment (4.41 ± 0.53 
munits/mg protein and 3.08 ± 0.22 Ilg/mg protein, respectively). Bars, 
SEM of duplicate experiments. 
increase in tyrosine hydroxylase activity; dopa oxidase activity 
showed a lag period of several hours, and then displayed a continu-
ous increase at a rate slightly lower than the one observed for tyro-
sine hydroxylation activity. Finally, a continuous increase in mela-
nin content can be seen, although variation occurs mainly in the first 
eight hours of treatment. 
The Km of OCT for L-dopachrome was estimated for cells with 
or without treatment with (X-MSH for 24 h . Km after treatment 
with the hormone, 150 j.lM, was slightly higher than the one ob-
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Figure 3. Time course, after treatment of B16 melanoma cells with 2 X 
10-7 M a-MSH, of (e) tyrosine hydroxylase, U /mg; (0) dopa oxidase; and 
(.a.) DCT specific activities, both expressed as mU/mg; as well as (II) mela-
nin content, expressed as Ilg/mg. Data variations were always lower than 
20%. 
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Table I. Effects of (X-MSH on B16 Melanoma Cells 
After 4 d of Treatment· 
Cell number (X 10- 6) 
Tyrosine hydroxylase 
Dopa oxidase 
DCT 
Melanin content 
Untreated 
4.3 ± 0.5 
1.7 ± 0.43 
5.18 ± 0.92 
7.83 ± 1.34 
3.57 ± 0.67 
Treated (%) 
2.1 ± 0.4 (49) 
9.23 ± 1.84 (543) 
14.55 ± 1.92 (281) 
5.40 ± 0.70 (69) 
8.0 ± 2.32 (224) 
, Cells were cultured in the presence or absence of2 X 10-7 M a-MSH for 4 d. Then 
they were harvested, solubilized, and tested for enzymatic activities, melanin, and 
protein content as described in Materials atld Methods. Tyrosine hydroxylase is expressed 
as U/ mg of protein, dopa oxidase and DCT are expressed as U / mg, and melanin 
content is expressed as Ilg/mg. Numbers in brackets indicate the percentage with 
respect to untreated cells. 
tained for control cells, 130 j.lM. However, this difference was not 
statistically significant. 
The superpotent (X-MSH analogue (4NorLeu, 70Phe)-(X-MSH 
was also employed in similar experiments instead of the hormone. 
This analogue has proved to be a very potent melanotropin that 
exhibits ultraprolonged activity [24], and therefore was used in 
order to prevent the possible hormone inactivation in cultures by 
the action of proteolytic enzymes present in the culture media. 
However, the effects produced by this analogue after 24 h were very 
similar to those produced by the native hormone. 
In order to get information about the long-term effect of (X-MSH 
on these enzymatic activities, B16 melanoma cells were cultured in 
the presence or absence of 2 X 10-7 M (X-MSH for 4 d (Table I). 
The results indicate a pattern similar to those obtained after 24 h, 
although the stimulatory effects on tyrosine hydroxylase and dopa 
oxidase activity increase up to 543 and 281 %, respectively. How-
ever, OCT is inhibited around 31 %. This inhibition is lower than 
the inhibition obtained after 1 or 2 d, suggesting a certain recovery 
of this activity after longer exposures (4 d) of cells to (X-MSH. Fi-
nally, the melanin content was maximum after 4 d, because the 
pigment is accumulated during a long period. 
Other melanogenesis-stimulating reagents were assayed in order 
to investigate their effects on OCT and dopa oxidase activities. 
Concentrations of these agents were chosen according to the range 
used by other authors in former studies and different melanoma cell 
lines, as follows: 1 mM theophylline [13], 0.5 mM IBMX [14], 
0.5 mM db-cAMP [10l, and two retinoids (retinoic acid and retinol) 
at concentration 0.01 mM [15] , were added to the cultures and after 
24 h the cells were harvested and solubilized. The results obtained 
are also shown in Figs 1 and 2. Cell viability after treatment with 
these melanogenic agents was similar to the case of (X-MSH, except 
in the case of theophylline, which showed the lowest cell viability 
(around 70%), and db-cAMP, which showed a viability almost 
identical to the control cells (98%). 
In all cases there was a decrease in OCT activity after treatment, 
in agreement with the results obtained for (X-MSH. There are in-
creases in both dopa oxidase activity and melanin content after 
treatment with these melanogenesis-stimulating reagents. It is 
worth pointing out that theophylline and IBMX, which produced 
the highest activation on dopa oxidase activity and highest accumu-
lation of melanin, did not produce the maximal inhibition on OCT. 
(X-MSH, whose effect on dopa oxidase was small, had a large effect 
on OCT inhibition. Thus, no correlation between the effects of 
those agents on tyrosinase and OCT activities could be shown. 
In addition, it is also noteworthy that no correlation existed be-
tween the effects of different treatments on the enzymatic activities 
and melanin content in the cells. Thus, cells treated with theophyl-
line exhibited maximal dopa oxidase activity, but the highest con-
tent of melanin was detected in cells treated with IBMX. (X-MSH 
and retinoids, which produced maximal inhibition of OCT, dis-
played a good correlation between stimulation of dopa oxidase activ-
ity and increase in the melanin content. However, db-cAMP also 
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displayed such a good correlation between dopa oxidase activity and 
melanin content, but the effect caused on OCT was the lowest one. 
DISCUSSION 
Several studies have been reported dealing with the action of a-
MSH on tyrosinase activity in different melanoma cell lines, such as 
Cloudman S-91 [10,26], B-16 [25-28], and JB/MS [19,25,28]. 
Generally, the hormone produced activation of tyrosinase activity 
with a concomitant increase in melanosynthesis. However, the 
magnitude of the reported activations of tyrosinase varies in a wide 
range, being as high as five- to tenfold in Cloud man S91 [6], B16 
[25,27]' and JB/MS [19,25,28]; 3.5 times [10] or only 1.5 times 
[29]' both in Cloudman S91; or even no activation in some JB/MS 
subclones [28] and human melanocytes [9]. 
An increase in the rate of "de novo" synthesis of tyrosinase, an 
activation of pre-existing enzyme molecules, and the removing of a 
tyrosinase inhibitor are the mechanisms proposed to account for this 
stimulation in tyrosinase activity. The findings that both a-MSH 
and theophylline stimulate to a different degree the dopa oxidase 
and tyrosine hydroxylase activities of tyrosinase seem to rule out the 
simplest explanation of an increased rate of enzyme synthesis as the 
only mechanism of tyrosinase stimulation. In turn, it has been re-
cently suggested that mammalian melanocytes could contain more 
than one protein with tyrosinase activity [19,30]. These proteins 
display similar biochemical and probably immunologic characteris-
tics, although their responses to melanogenic activators could be 
different. Therefore, the possibility of a differential activation of 
two or more tyrosinases cannot be ruled out, and deserves further 
investigation. 
Nevertheless, tyrosinase is not the only enzyme involved in the 
regulation of melanogenesis. The existence of OCT in melanoma 
cells, catalyzing the transformation of dopachrome to OHICA [4], 
is now well established. The fact that B16 mouse melanoma cells 
contain similar or even higher catalytic amounts of OCT than of 
tyrosinase could indicate that OCT could be a target for the a-
MSH - mediated regulation of mammalian melanogenesis. . 
After treatment with a-MSH, a large decrease in OCT activity is 
produced. This decrease is accompanied by an increment in tyrosin-
ase activity and melanin content. A similar effect is provoked by 
other melanization stimulating agents, because all of them de-
creased OCT activity. However, some of them increased tyrosinase 
activities more than a-MSH. 
The very similar Km for OCT obtained from control and cells 
submitted to treatment with the hormone could suggest that the 
decrease in activity is not due to post-translational modifications in 
the enzyme molecule. However, a small difference could be de-
tected, and this assumption is not totally conclusive. Regarding this 
matter, studies using an anti-OCT antibody are planned in our 
laboratory . 
Bearing in mind the activatory effect of melanotropins on melan-
ogenesis, it might be thought that a-MSH should increase all steps 
of this pathway. Thus, OCT activity should be also enhanced. How-
ever, it is necessary to consider that, in addition to the dopachrome 
tautomerization reaction yielding OHICA, there is an alternative 
spontaneous way for dopachrome conversion yielding OHl. This 
intermediate is less stable than OHICA and could also contribute to 
melanin formation. Therefore, melanin accumulation can be en-
hanced even in the case of OCT inhibition. In that situation, the 
formation ofOHI and the corresponding indolequinone is not pre-
vented, leading to the uncontrollable polymerization of these inter-
mediates, highly cytotoxic [31]. This could be the reason for the 
lower cell viability observed for cells treated with melanogenic 
agents. Accordingly, the agent showing the lowest inhibitory effect 
on OCT, db-cAMP, was also the agent showing the highest cell 
viability. 
The fact that agents prolonging cAMP half-life, or able to substi-
tute for it, mimicked the MSH action, supports the idea that cAMP 
is the second messenger for signal transmission after hormone bind-
ing to melanoma cell receptors. All these agents produced an inhibi-
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tion of OCT activity, and a stimulation of tyrosinase activity. How-
ever, the lack of correlation among the variations of tyrosi~e 
hydroxylase, dopa oxidase, and OCT activities suggests the eXIS-
tence of other mechanisms, besides cAMP, responsible for hormone 
action. This is also suggested by the results obtained after treatme~t 
with retinoids. The decrease in OCT activity and the increase III 
tyrosinase provoked by these agents cannot be ascribed to a cAM~­
mediated process, because the possibility that retinoids act via act~­
vation of adenylate cyclase has been previously ruled out [15]. Simi-
lar interpretation has been suggested to account for the action of 
prostaglandins on melanogenesis [14]. 
The decrease in OCT activity provoked by melanogenic agents 
seems to be characteristic for B16 melanoma cells. In Cloudman S91 
cells, doyachrome conversion factor activity is not affected by 
P-MSH l1], or even stimulated [16]. This stimulation has been a!so 
reported for dopachrome oxidoreductase in hairbulbs from nuce 
[17]. a-MSH provoked a very slight activation of OCT inJB/~S 
melanoma cells [19]. It has been reported that the ratio of melanlfi 
formation to tyrosine hydroxylase activities after MSH treatment 
decreases in B16 but does not inJB/MS melanoma cells [25], su~­
gesting that B16 behaves different from the other cell lines. ThiS 
could be related to the differences in the response of OCT from B 16 
melanoma cells to melanogenic agents. . . 
In summary, the molecular reasons for the decrease in OCT actiV-
ity in B-16 melanoma cells after treatment with melanogenic agentS 
needs further investigation. Comprehension of the mechanisms to 
account for tyrosinase activation could help to elucidate the mecha-
nisms of OCT inhibition and the possible differences among cell 
lines. 
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